A5065430193- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- Cancer Risks and Factors
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- Endometrial and Cervical Cancer Treatments
- Multiple and Secondary Primary Cancers
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Economic and Financial Impacts of Cancer
- Glioma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Lymphocytic Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Breast Lesions and Carcinomas
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Intraperitoneal and Appendiceal Malignancies
Ankara Onkoloji Eğitim ve Araştırma Hastanesi
2017-2025
Sağlık Bilimleri Üniversitesi
2019-2025
University of Health Science
2023-2024
University of Health Sciences
2024
Ministry of Health
2021-2024
Memorial Ankara Hospital
2021
University of Health Sciences Antigua
2020
Hacettepe University
2007-2018
Hacettepe University Hospital
2015-2017
Cancer Institute (WIA)
2015-2016
The relation between higher body mass index (BMI) and pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is a controversial issue according the data of Western Asian patients. aim this study evaluate BMI pCR NAC discuss importance outcomes Turkish BC patients as bridging country Europe Asia.Of 4423 diagnosed years 1994 2015 Hacettepe University Cancer Institute, 295 female with stage II III were enrolled study. Three different group divisions done...
Background and Objectives: Breast cancer (BC) is the most prevalent globally, with a significant mortality rate, especially among women. While advances in treatment have reduced BC mortality, cardiovascular complications resulting from anticancer therapies become major concern. The autonomic nervous system (ANS) may be affected patients it assessed heart rate variability (HRV). aim of this study was to investigate prevalence impaired HRV, its predictors, clinical impacts patients. Materials...
The aims of this study were to comprehensively describe the psychosocial and medical characteristics women who initiated tamoxifen or aromatase inhibitors for breast cancer compare levels emotional distress according their (tumor demographics, treatment type, duration) (self-esteem, perceived social support, sociodemographic) characteristics. A total 104 currently receiving was recruited from outpatient clinics they asked complete self-report questionnaires including Rosenberg Self-Esteem...
Abstract Background: Non-small cell lung cancer (NSCLC) is often diagnosed late with many patients (pts) not responding to first line therapy or only for a limited time. BNT116 an intravenously administered uridine RNA-based lipoplex vaccine comprising six mRNAs (MAGE A3, CLDN6, KK-LC-1, PRAME, MAGE A4, C1), each encoding tumor-associated antigen (TAA) frequently expressed in NSCLC. Here, we present preliminary results from pts advanced unresectable metastatic NSCLC (ECOG 0-1) receiving +...
Background and Objectives: Bone metastases in patients can cause significant quality-of-life declines due to skeletal-related events (SREs). SRE is defined as the occurrence of radiotherapy for bone pain, pathologic fracture, surgery, spinal cord compression, or hypercalcemia. Bone-modifying agents (BMAs), such denosumab zoledronic acid, are crucial reducing frequency severity SREs. The inhibition cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has emerged standard treatment hormone...
Abstract Aims and Objectives The prognostic value of nutritional status in HR+/HER2- metastatic breast cancer (mBC) patients treated with CDK4/6 inhibitors (CDK4/6is) endocrine therapy (ET) is unclear. Methods/Materials effect PNI values before starting CDK 4/6i on patient prognosis was retrospectively analyzed. Results A total 431 were evaluated. After 35.7 months follow-up, the median overall survival (mOS) 46.3 (95% CI, 29.7–62.8). PNI-low group had decreased progression-free compared to...
In this Turkish Oncology Group study, we aimed to evaluate the effectiveness of trastuzumab emtansine (TDM1) in adjuvant treatment early-stage human epidermal growth factor receptor-2 (HER2)-positive breast cancer with residual disease using real-life data. A total 13 centers participated study between September 2019 and October 2024. Patients HER2-positive who underwent surgery after completing neoadjuvant chemotherapy HER2-targeted therapies had invasive or axillary lymph nodes received...
Background and Objectives: Conversion surgery for liver metastatic colorectal cancer (mCRC) has been associated with prolonged survival. This study aimed to evaluate the efficacy safety of integrating biological therapies fluorouracil-based induction chemotherapy in patients isolated mCRC who subsequently underwent curative resection both primary tumor metastases. Materials Methods: multicenter, retrospective study, conducted by Turkish Oncology Group (TOG), included 116 from 11 tertiary...
Life-threatening conditions such as cancer can evoke demoralization, which is characterized by feelings of meaninglessness, hopelessness, and helplessness. Assessing demoralization in patients crucial. This study aimed to evaluate the psychometric properties Turkish version Demoralization Scale-II (TDS-II) explore its relationship with sociodemographic disease-related factors. included 287 patients, 265 whom completed final analysis. The participants TDS-II, Patient Health Questionnaire-9...
e20501 Background: The role of biomarkers in the treatment non-small cell lung cancer is increasing. Biomarker evaluation performed almost all diagnosed patients and treatments are applied according to this evaluation. In study, frequency testing rates with Turkey were investigated. Methods: "Registurk-Lung" study conducted our country, histopathological, molecular, radiological clinical data more than 9000 from 42 centers collected between December 2021 January 2024 within scope...
e17068 Background: Prostate-specific membrane antigen (PSMA) is a key therapeutic target in metastatic castration-resistant prostate cancer (mCRPC). Elevated PSMA expression predicts the efficacy of ¹⁷⁷Lu-PSMA-617 radioligand therapy. Enzalutamide, an androgen receptor pathway inhibitor (ARPi), has been shown to upregulate expression. This study evaluates impact prior ARPi selection on treatment outcomes, including expression, progression-free survival (PFS), and overall (OS), patients...
e15006 Background: RS-0139 is a tumor-targeted prodrug designed to enhance the therapeutic index of docetaxel (DTX) by selectively delivering active agent tumor tissues. DTX covalently bound polymer backbone, together with targeting peptide, which shows high affinity α v β 3 , 5 and 6 integrin receptors highly overexpressed on cell surface. Once up-taken cell, covalent bond cleaved release DTX. gains investigational new drug status since modified for targeted treatment. Physical properties...
e15507 Background: Mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) CRC tumors constitute of 5% mCRC. Immunotherapy is a new standard, but it difficult to give all. 5FU based treatment with antiEGFRs in RAS/BRAF-wt or bevacizumab (B) used Data limited for the efficacy B dMMR/MSI-H mCRC due small number cases population trials. Aims : Evaluation prognostic factors & 1 st line B/antiEGFRs Methods: patients (pts) were evaluated retrospectively. Results: 132 included....
Aims: Phase III studies investigating CDK 4/6 inhibitors have failed to identify significant predictive or prognostic markers that aid clinicians in therapeutic decision-making. Given the complex treatment landscape breast cancer, identifying patient and tumor characteristics optimize utilization of across diverse approaches is crucial. In our study, we aimed evaluate role progesterone receptor (PR) expression levels patients with estrogen (ER)-positive human epidermal growth factor 2...
Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data who received at least two cycles combination chemotherapy were retrospectively recorded. Results: median age 51 was 56 (range: 33-75) years. complete response rate 10.4% partial 43.7%. objective 54.1%. Median progression-free survival 15.9 months (95% CI: 9.1-22.6) overall 42.5 37.2-47.8). Conclusion: Bevacizumab is an effective option for treating
This study addresses the gap in understanding prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor (VEGF)-based therapy. A retrospective multicenter (n = 34) explored HIF-1 via immunohistochemistry treated with platinum chemotherapy and bevacizumab. Median progression-free survival (PFS) was significantly lower low score group compared to high (4.9 vs...
Bone wax is commonly used in neurosurgical practice as a haemostatic and sealing agent. It safe agent, but may lead to adverse effects such infection, epistaxsis, allergic reaction or foreign body granuloma. There are very few reported cases of the neurological complications remnant bone subdural subarachnoid space. The authors report case granuloma infiltration through medulla oblongata due space after posterior fossa decompressive surgery.